OncoCyte Corp. (OCX) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Coeptis Therapeutics Holdings, Inc.

OncoCyte Corp.

Pieris Pharmaceuticals, Inc.

Enlivex Therapeutics Ltd.

Leap Therapeutics, Inc.

Cyclo Therapeutics, Inc.

IN8bio, Inc.

Alaunos Therapeutics, Inc.

Co-Diagnostics, Inc.

Unity Biotechnology, Inc.

Elevation Oncology, Inc.

Why is OncoCyte Corp. ?

With a Negative Book Value, the company has a Weak Long Term Fundamental Strength

Poor long term growth as Operating profit has grown by an annual rate 2.08% of over the last 5 years
Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -33.98

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 17.68%, its profits have fallen by -13.2%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is OncoCyte Corp. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

OncoCyte Corp.

17.68%

0.64

91.20%

S&P 500

14.9%

0.77

19.29%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

39.27%

EBIT Growth (5y)

2.08%

EBIT to Interest (avg)

-33.98

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-2.90

Sales to Capital Employed (avg)

0.16

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

53.96%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-15.88

EV to EBIT

-4.92

EV to EBITDA

-5.37

EV to Capital Employed

-4.75

EV to Sales

29.13

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

Negative BV

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bearish

OBV

Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

14What is working for the Company

NET SALES(HY)

At USD 0.78 MM has Grown at 255.25%

NET PROFIT(HY)

Higher at USD -14.41 MM

RAW MATERIAL COST(Y)

Fallen by -30.06% (YoY

DEBTORS TURNOVER RATIO(HY)

Highest at 18.85 times

-12What is not working for the Company

INTEREST(HY)

At USD 0.05 MM has Grown at 38.46%

ROCE(HY)

Lowest at -23,603.11%

DEBT-EQUITY RATIO (HY)

Highest at 177.19 %

OPERATING PROFIT(Q)

Lowest at USD -7.09 MM

PRE-TAX PROFIT(Q)

Lowest at USD -7.48 MM

NET PROFIT(Q)

Lowest at USD -7.48 MM

Here's what is working for OncoCyte Corp.

Net Sales

At USD 0.78 MM has Grown at 255.25%

Year on Year (YoY)

MOJO Watch

Sales trend is very positive

Net Sales (USD MM)

Debtors Turnover Ratio

Highest at 18.85 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Raw Material Cost

Fallen by -30.06% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for OncoCyte Corp.

Interest

At USD 0.05 MM has Grown at 38.46%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Operating Profit

Lowest at USD -7.09 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (USD MM)

Pre-Tax Profit

Lowest at USD -7.48 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (USD MM)

Net Profit

Lowest at USD -7.48 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is negative

Net Profit (USD MM)

Debt-Equity Ratio

Highest at 177.19 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio